Table 2: Descriptive characteristics by response to CGRP MABs.
|
|
Response Predictors |
||||
|
Non-responders |
Responders |
p |
|||
|
Age Mean (SD) |
43.4 |
-10.2 |
38.5 |
-14.2 |
0.12 |
|
Biologic Sex |
0.94 |
||||
|
Male |
4 |
-14.8 |
9 |
-18.4 |
|
|
Female |
23 |
-85.2 |
40 |
-81.6 |
|
|
MAB Name |
0.37 |
||||
|
Eptinezumab |
0 |
0 |
1 |
-2 |
|
|
Erenumab |
14 |
-51.9 |
16 |
-32.7 |
|
|
Fremanezumab |
10 |
-37 |
26 |
-53.1 |
|
|
Galcanezumab |
3 |
-11.1 |
6 |
-12.2 |
|
|
Allodynia |
0.17 |
||||
|
No |
21 |
-77.8 |
45 |
-91.8 |
|
|
Yes |
6 |
-22.2 |
4 |
-8.2 |
|
|
Aura |
0.38 |
||||
|
No |
22 |
-81.5 |
34 |
-69.4 |
|
|
Yes |
5 |
-18.5 |
15 |
-30.6 |
|
|
Phono/Photo Phobia |
0.4 |
||||
|
No |
4 |
-14.8 |
3 |
-6.1 |
|
|
Yes |
23 |
-85.2 |
46 |
-93.9 |
|
|
Nausea & Vomiting |
1 |
||||
|
No |
5 |
-18.5 |
9 |
-18.4 |
|
|
Yes |
22 |
-81.5 |
40 |
-81.6 |
|
|
Autonomic Symptoms |
0.014 |
||||
|
No |
19 |
-70.4 |
46 |
-93.9 |
|
|
Yes |
8 |
-29.6 |
3 |
-6.1 |
|
|
Chronic migraine |
|||||
|
No |
3 |
-11.1 |
18 |
-36.7 |
0.034 |
|
Yes |
24 |
-88.9 |
31 |
-63.3 |
|
|
Duration of migraine disorder - Mean (SD) |
17.4 |
-14.4 |
20.1 |
-15.9 |
0.47 |
|
Post Traumatic |
0.74 |
||||
|
No |
24 |
-88.9 |
46 |
-93.9 |
|
|
Yes |
3 |
-11.1 |
3 |
-6.1 |
|
|
BMI > 30 |
0.24 |
||||
|
No |
12 |
-44.4 |
30 |
-61.2 |
|
|
Yes |
15 |
-55.6 |
19 |
-38.8 |
|
|
|
|
|
|
|
|
|
Total |
27 |
-35.3 |
49 |
-64.7 |
|
All values are N (%) except where noted.